Abstract
This report summarizes the results of the 2nd EQAsia Matrix EQA trial of the EQAsia project (Matrix EQA 2022), a Fleming Fund Regional Grant aiming to strengthen the provision of External Quality Assessment (EQA) services across the One Health sector among National Reference Laboratories / Centres of Excellence in South and Southeast Asia. EQAsia has been granted a 2nd phase (July 2023 to December 2025) to continue to deliver the established EQA for both the Human Health (HH sector) and Food and Animal Health (AH sector) laboratories in the region.
The trial was carried out in September-November 2022 and included isolation of E. coli presumptive of producing either ESBL, AmpC or carbapenemase enzymes from lyophilized cultures mimicking meat content, followed by antimicrobial susceptibility testing (AST) of the isolates.
A total of two HH and three AH laboratories participated and submitted results for the Matrix EQA. These laboratories are from four countries situated in South and Southeast Asia (Bangladesh, Laos People Democratic Republic, Pakistan, and Sri Lanka).
The participants used the recommended methods for selective isolation of the presumptive ESBL-, AmpC- or carbapenemase-producing E. coli isolates from the cultures mimicking meat content and applied biochemical tests for confirmation of the bacterial identification.
The four samples expected to be positive for growth of presumptive ESBL-, AmpC- or carbapenemase-producing E. coli were correctly identified as positive by at least 60% of the laboratories, whereas none of the participants correctly identified the negative sample.
Four of the participating laboratories submitted results for antimicrobial susceptibility testing and presented an average deviation of 5.8% (ranging from 0.5 to 12.9%) in terms of AST performance.
The trial was carried out in September-November 2022 and included isolation of E. coli presumptive of producing either ESBL, AmpC or carbapenemase enzymes from lyophilized cultures mimicking meat content, followed by antimicrobial susceptibility testing (AST) of the isolates.
A total of two HH and three AH laboratories participated and submitted results for the Matrix EQA. These laboratories are from four countries situated in South and Southeast Asia (Bangladesh, Laos People Democratic Republic, Pakistan, and Sri Lanka).
The participants used the recommended methods for selective isolation of the presumptive ESBL-, AmpC- or carbapenemase-producing E. coli isolates from the cultures mimicking meat content and applied biochemical tests for confirmation of the bacterial identification.
The four samples expected to be positive for growth of presumptive ESBL-, AmpC- or carbapenemase-producing E. coli were correctly identified as positive by at least 60% of the laboratories, whereas none of the participants correctly identified the negative sample.
Four of the participating laboratories submitted results for antimicrobial susceptibility testing and presented an average deviation of 5.8% (ranging from 0.5 to 12.9%) in terms of AST performance.
Original language | English |
---|
Publisher | National Food Institute |
---|---|
Number of pages | 34 |
ISBN (Print) | 978-87-7586-015-9 |
Publication status | Published - 2023 |